Skip Navigation



Brain Advance Access published online on August 19, 2004

Brain, doi:10.1093/brain/awh269
© 2004 by Guarantors of Brain
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
127/11/2452    most recent
awh269v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wang, G.-J.
Right arrow Articles by Fowler, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, G.-J.
Right arrow Articles by Fowler, J. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received May 7, 2004
Revised June 10, 2004
Accepted June 14, 2004

Article

Decreased brain dopaminergic transporters in HIV-associated dementia patients

Gene-Jack Wang 1, Linda Chang 1*, Nora D. Volkow 2, Frank Telang 2, Jean Logan 1, Thomas Ernst 1, Joanna S. Fowler 1

1 Medical and Chemistry Departments, Brookhaven National Laboratory, Upton, NY, USA
2 National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

* To whom correspondence should be addressed. E-mail: lchang{at}hawaii.edu.


   Abstract

Summary HIV has a propensity to invade subcortical regions of the brain, which may lead to a subcortical dementia termed HIV-cognitive motor complex. Therefore, we aimed to assess whether dopamine (DA) D2 receptors and transporters (DAT) are affected in the basal ganglia of subjects with HIV, and how these changes relate to dementia status. Fifteen HIV subjects (age 44.5 ± 11 years; CD4 185 ± 130/mm3) and 13 seronegative controls (42 ± 12 years) were evaluated with PET to assess availability of DAT ([11C]cocaine) and DA D2 receptor ([11C]raclopride). HIV patients with associated dementia (HAD), but not those without dementia (ND) had significantly lower DAT availability in putamen (-19.3%, P = 0.009) and ventral striatum (-13.6%, P = 0.03) compared with seronegative controls. Higher plasma viral load in the HIV dementia patients correlated with lower DAT in the caudate (r = -0.7, P = 0.02) and putamen (r = -0.69, P = 0.03). DA D2 receptor availability, however, showed mild and non-significant decreases in HIV patients. These results provide the first evidence of DA terminal injury in HIV dementia patients, and suggest that decreased DAT may contribute to the pathogenesis of HIV dementia. The greater DAT decrease in the putamen than in the caudate parallels that observed in Parkinson's disease. The inverse relationship between viral burden and DAT availability further supports HIV-mediated neurotoxicity to dopaminergic terminals.

Keywords: HIV; dopamine; dementia; PET; cocaine.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. Zhu, C. F. Mactutus, D. R. Wallace, and R. M. Booze
HIV-1 Tat Protein-Induced Rapid and Reversible Decrease in [3H]Dopamine Uptake: Dissociation of [3H]Dopamine Uptake and [3H]2{beta}-Carbomethoxy-3-{beta}-(4-fluorophenyl)tropane (WIN 35,428) Binding in Rat Striatal Synaptosomes
J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1071 - 1083.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
D. A. Hammoud, J. M. Hoffman, and M. G. Pomper
Molecular Neuroimaging: From Conventional to Emerging Techniques
Radiology, October 1, 2007; 245(1): 21 - 42.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Fitting, R. M. Booze, and C. F. Mactutus
Neonatal Intrahippocampal Glycoprotein 120 Injection: The Role of Dopaminergic Alterations in Prepulse Inhibition in Adult Rats
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1352 - 1358.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.